Nikhila Sampath Kumar

PGY3 IM @UAMSHealth @UAMSintmedicine | Aspiring Hem/Onc physician |🦀🧬🔬#WomenInOncology

[Nikhila Sampath Kumar @NikhilaSKumar]

Proud to represent @uamscancer at ASCO #GU26! 🧬
Come find me at C16 to learn more about SGLT2 inhibitor use in renal cell cancer💊

[The Permanente Journal @PermanenteJ]

This report describes a young patient with a well-differentiated neuroendocrine tumor arising in a retroperitoneal mature cystic teratoma who achieved disease free status following surgical resection.

https://t.co/cuJxgob1xe @NikhilaSKumar

[Nikhila Sampath Kumar @NikhilaSKumar]

@LinaAlQirem @uamscancer Thank you Lina❤️🥹

[Nikhila Sampath Kumar @NikhilaSKumar]

Proud to represent @uamscancer at ASCO #GU26! 🧬
Come find me at C16 to learn more about SGLT2 inhibitor use in renal cell cancer💊

[Giannis Mountzios @g_mountzios]

#ASCO25 After 30 years of failed trials, #tarlatamab changes SoC for our pts with relapsed #SCLC :

✅ mOS: 13.6 vs 8.3 months, HR=0.6, p<0.001
✅ improved QoL (dyspnea and cough)
✅ 27% vs 62% G3 TRAEs

Grateful to all collaborators, @Amgen science team and above all our pts

[Dr Amol Akhade @SuyogCancer]

How to select pts with HCC for various local therapies?
RFA ,MWA , TACE , SIRT , SBRT . Useful for clinical decision-making.
Taken from #asco25 @ASCO
Do u agree ? @dr_yakupergun @NiuSanford @jryckman3 @OncoAlert @medicalwatchBC

[Samer Al Hadidi, MD,MS,FACP @HadidiSamer]

Check our long term follow up of earlier total therapy protocols in Arkansas @JAMAOnc @UAMSMyeloma #mmsm

➡️ https://t.co/1BHMmpWC6V

✅ With time limited therapy&median follow up of ~17 years of 1202 patients, we estimate one out of three patients are cured from their multiple myeloma based on relative survival rate (based on US population expected survival)

✅ Roughly one in four patients survived beyond 20 years from diagnosis in TT2 arm A

[Rami Manochakian MD, FASCO @RManochakian]

“When Cancer Hits the Oncologist’s Home”. On the anniversary of his passing, I share a piece I published @OncJournal on my experience as a cancer doctor, during my father-in-law’s cancer journey. He’s a great man who beat cancer by fighting the cancer. RIP
https://t.co/nJdpVxkNMY

[Memorial Sloan Kettering Cancer Center @MSKCancerCenter]

Meatball, a cancer therapy dog, made his rounds at @ASCO. #ASCO25

[Arya Roy @royaryam]

Excited to present our research today at #ASCO25 @ASCO! IMG exhibit higher research productivity compared to AMGs - matrix that helps PDs to recruit more IMGs to hemonc fellowship programs! @IMG_Oncologists @NazliDizman @ArdeshirFatemeh @ZiadBakouny @DrChoueiri @OhioStateMedOnc

[Moffitt Cancer Center @MoffittNews]

Live from #ASCO25: Andrew Kuykendall, MD, (@KuykendallMd) joins us to share the practice changing results from the VERIFY study that he presented at the @ASCO Plenary Session.

Key takeaways:

• Rusfertide significantly reduced the need for therapeutic phlebotomies. 77% of patients maintained hematocrit control without additional blood draws, compared to 33% on placebo.

• Patients reported meaningful improvements in fatigue, one of the most common and life-disrupting symptoms of polycythemia vera.

• The treatment was well tolerated, with mostly mild injection site reactions and rare serious side effects, offering a promising new option for long-term disease management.

#MoffittASCO25

[UAMS Internal Medicine Residency @UAMSintmedicine]

Congratulations to our new @UAMSintmedicine class!! We are so excited to have you!!🎉🎉